Bernadette Marquez-Nostra, PhD

• David Labaree
• Fangyong Li
• Jason Cai
• Jie Tong
• Michael Kapinos
• Nabeel Nabulsi

Radionuclide Imaging; Biomedical Research; Positron-Emission Tomography; Single Photon Emission Computed Tomography Computed Tomography

• Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation.Marquez BV, Beck HE, Aweda TA, Phinney B, Holsclaw C, Jewell W, Tran D, Day JJ, Peiris MN, Nwosu C, Lebrilla C, Meares CF. Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation. Bioconjugate Chemistry 2012, 23: 1080-9. PMID: 22537066, PMCID: PMC3431436, DOI: 10.1021/bc300114d.
• Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.Marquez BV, Ikotun OF, Parry JJ, Rogers BE, Meares CF, Lapi SE. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2014, 55: 1029-34. PMID: 24732153, DOI: 10.2967/jnumed.113.130898.
• [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast CancerLaforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging And Biology 2016, 18: 952-959. PMID: 27146421, PMCID: PMC5096950, DOI: 10.1007/s11307-016-0951-z.
• Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancerCavaliere A, Sun S, Lee S, Bodner J, Li Z, Huang Y, Moores SL, Marquez-Nostra B. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 48: 383-394. PMID: 32770372, PMCID: PMC7855369, DOI: 10.1007/s00259-020-04978-6.
• [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancerLee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer. Molecular Cancer Therapeutics 2022, 21: molcanther.0590.2021. PMID: 35027482, PMCID: PMC8898259, DOI: 10.1158/1535-7163.mct-21-0590.
• Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens.Belitzky E, Cavaliere A, Rajabimoghadam K, Marquez-Nostra B. Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens. Journal Of Visualized Experiments 2022 PMID: 35815982, DOI: 10.3791/63927.
• PET Imaging in Animal Models of Alzheimer’s DiseaseChen B, Marquez-Nostra B, Belitzky E, Toyonaga T, Tong J, Huang Y, Cai Z. PET Imaging in Animal Models of Alzheimer’s Disease. Frontiers In Neuroscience 2022, 16: 872509. PMID: 35685772, PMCID: PMC9171374, DOI: 10.3389/fnins.2022.872509.
• P-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in miceTong J, Chen B, Alluri S, Gu J, Zheng M, Zheng C, Felchner Z, Gao H, Zhang L, Kapinos M, Labaree D, Ropchan J, Nabulsi N, Marquez-Nostra B, Carson R, Huang Y, Cai Z. P-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in mice. Nuclear Medicine And Biology 2022, 108: s214. DOI: 10.1016/s0969-8051(22)00439-5.
• Clinical Evaluation of Nuclear Imaging Agents in Breast CancerLi Z, Aboian MS, Zhu X, Marquez-Nostra B. Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers 2022, 14: 2103. PMID: 35565232, PMCID: PMC9101155, DOI: 10.3390/cancers14092103.
• Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast CancerFang H, Cavaliere A, Li Z, Huang Y, Marquez-Nostra B. Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Frontiers In Pharmacology 2021, 12: 627693. PMID: 33986665, PMCID: PMC8111013, DOI: 10.3389/fphar.2021.627693.
• The Radiopharmaceutical Chemistry of Zirconium-89Marquez-Nostra B, Viola N. The Radiopharmaceutical Chemistry of Zirconium-89. 2019, 371-390. DOI: 10.1007/978-3-319-98947-1_21.
• Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 TherapyMassicano AVF, Lee S, Crenshaw BK, Aweda TA, Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. Cancer Biotherapy & Radiopharmaceuticals 2019, 34: 209-217. PMID: 30676778, PMCID: PMC7227434, DOI: 10.1089/cbr.2018.2654.
• Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancerDehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research And Treatment 2018, 169: 523-530. PMID: 29442264, PMCID: PMC5955803, DOI: 10.1007/s10549-018-4696-z.
• Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma XenograftsYoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts. Journal Of Nuclear Medicine 2018, 59: 1219-1224. PMID: 29348316, PMCID: PMC6071500, DOI: 10.2967/jnumed.117.203299.
• Targeting HER2 in Nuclear Medicine for Imaging and TherapyMassicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging 2018, 17: 1536012117745386. PMID: 29357745, PMCID: PMC5784567, DOI: 10.1177/1536012117745386.
• Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agentMarquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, X. C, Lapi SE. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Oncotarget 2017, 5: 104303-104314. PMID: 29262642, PMCID: PMC5732808, DOI: 10.18632/oncotarget.22228.
• New Methods for the Site-Selective Placement of Peptides on a Microelectrode Array: Probing VEGF-v107 Binding as Proof of Concept.Graaf MD, Marquez BV, Yeh NH, Lapi SE, Moeller KD. New Methods for the Site-Selective Placement of Peptides on a Microelectrode Array: Probing VEGF-v107 Binding as Proof of Concept. ACS Chemical Biology 2016, 11: 2829-2837. PMID: 27556638, DOI: 10.1021/acschembio.6b00685.
• Pretargeted Immuno-PET: Overcoming Limitations of Space and Time.Marquez BV, Lapi SE. Pretargeted Immuno-PET: Overcoming Limitations of Space and Time. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2016, 57: 332-3. PMID: 26659352, DOI: 10.2967/jnumed.115.168096.
• Harvesting (67)Cu from the Collection of a Secondary Beam Cocktail at the National Superconducting Cyclotron Laboratory.Mastren T, Pen A, Loveless S, Marquez BV, Bollinger E, Marois B, Hubley N, Brown K, Morrissey DJ, Peaslee GF, Lapi SE. Harvesting (67)Cu from the Collection of a Secondary Beam Cocktail at the National Superconducting Cyclotron Laboratory. Analytical Chemistry 2015, 87: 10323-9. PMID: 26403524, DOI: 10.1021/acs.analchem.5b02322.
• Cyclotron Production of High-Specific Activity 55Co and In Vivo Evaluation of the Stability of 55Co Metal-Chelate-Peptide Complexes.Mastren T, Marquez BV, Sultan DE, Bollinger E, Eisenbeis P, Voller T, Lapi SE. Cyclotron Production of High-Specific Activity 55Co and In Vivo Evaluation of the Stability of 55Co Metal-Chelate-Peptide Complexes. Molecular Imaging 2015, 14: 526-33. PMID: 26505224, PMCID: PMC4863226, DOI: 10.2310/7290.2015.00025.
• Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts. Molecular Pharmaceutics 2014, 11: 3988-95. PMID: 25058168, PMCID: PMC4224522, DOI: 10.1021/mp500323d.
• Investigation of a vitamin B12 conjugate as a PET imaging probe.Ikotun OF, Marquez BV, Fazen CH, Kahkoska AR, Doyle RP, Lapi SE. Investigation of a vitamin B12 conjugate as a PET imaging probe. ChemMedChem 2014, 9: 1244-51. PMID: 24753453, DOI: 10.1002/cmdc.201400048.
• Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread.Marquez BV, Zheleznyak A, Lapi SE. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2014, 55: 708-9. PMID: 24665087, DOI: 10.2967/jnumed.113.136234.
• Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET.Ikotun OF, Marquez BV, Huang C, Masuko K, Daiji M, Masuko T, McConathy J, Lapi SE. Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET. PloS One 2013, 8: e77476. PMID: 24143237, PMCID: PMC3797081, DOI: 10.1371/journal.pone.0077476.
• New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation.Aweda TA, Eskandari V, Kukis DL, Boucher DL, Marquez BV, Beck HE, Mitchell GS, Cherry SR, Meares CF. New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation. Bioconjugate Chemistry 2011, 22: 1479-83. PMID: 21755984, PMCID: PMC3158659, DOI: 10.1021/bc2002049.
• Chemically modified antibodies as diagnostic imaging agents.Day JJ, Marquez BV, Beck HE, Aweda TA, Gawande PD, Meares CF. Chemically modified antibodies as diagnostic imaging agents. Current Opinion In Chemical Biology 2010, 14: 803-9. PMID: 20952245, PMCID: PMC3010408, DOI: 10.1016/j.cbpa.2010.09.015.
• Effect of structure in benzaldehyde oximes on the formation of aldehydes and nitriles under photoinduced electron-transfer conditions.de Lijser HJ, Hsu S, Marquez BV, Park A, Sanguantrakun N, Sawyer JR. Effect of structure in benzaldehyde oximes on the formation of aldehydes and nitriles under photoinduced electron-transfer conditions. The Journal Of Organic Chemistry 2006, 71: 7785-92. PMID: 16995687, DOI: 10.1021/jo061325m.